|
SPCS3 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 3.31934479902429E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.8296000270368E-09 |
| Normal-vs-Stage2 |
6.26329999999786E-05 |
| Normal-vs-Stage3 |
1.02584607475364E-13 |
| Normal-vs-Stage4 |
1.63080660087189E-12 |
| Stage1-vs-Stage2 |
6.883800E-01 |
| Stage1-vs-Stage3 |
1.922470E-03 |
| Stage1-vs-Stage4 |
5.65109999999258E-05 |
| Stage2-vs-Stage3 |
1.694450E-02 |
| Stage2-vs-Stage4 |
9.354500E-04 |
| Stage3-vs-Stage4 |
1.036430E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
8.43769498715119E-15 |
| Normal-vs-AfricanAmerican |
1.70364999999562E-05 |
| Normal-vs-Asian |
3.60110052888274E-10 |
| Caucasian-vs-AfricanAmerican |
9.186800E-01 |
| Caucasian-vs-Asian |
9.789600E-01 |
| AfricanAmerican-vs-Asian |
9.437200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.30184751867546E-12 |
| Normal-vs-Female |
6.12629946772358E-11 |
| Male-vs-Female |
1.385760E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
7.76200004271033E-09 |
| Normal-vs-Age(41-60Yrs) |
1.8490764475132E-12 |
| Normal-vs-Age(61-80Yrs) |
5.82820458561173E-11 |
| Normal-vs-Age(81-100Yrs) |
3.618400E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
9.508300E-02 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.188240E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
5.812400E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
8.581800E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
2.692400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
2.534000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
2.26700000000024E-05 |
| Classical-VS-Follicular |
2.616700E-03 |
| Classical-VS-Other |
1.635160E-01 |
| Classical-VS-Normal |
1.67832414632585E-12 |
| Tall-VS-Follicular |
2.8073000035711E-08 |
| Tall-VS-Other |
7.196000E-01 |
| Tall-VS-Normal |
3.33066907387547E-16 |
| Follicular-VS-Other |
4.159700E-03 |
| Follicular-VS-Normal |
8.212900E-04 |
| Other-VS-Normal |
2.173399999994E-05 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
9.10209999593903E-08 |
| Normal-vs-N1 |
4.9960036108132E-15 |
| N0-vs-N1 |
2.11829999999802E-05 |
|
|
